Pulmonary Edema News and Research

RSS

Gas transfer excels in predicting mortality in COPD

Researchers say that measuring gas transfer is the most effective way to predict mortality in chronic obstructive pulmonary disease, after finding that it outperformed both spirometry and plethysmography for the purpose.

3 Oct 2013

Harvard University receives grant to use organs-on-chips device to test human response to radiation

A team at the Wyss Institute for Biologically Inspired Engineering at Harvard University has received a $5.6 million grant award from the United States Food and Drug Administration (FDA) to use its Organs-on-Chips technology for a novel application of keen interest to national security and health officials: to test human physiological responses to radiation, and to evaluate drugs designed to counter those effects.

13 Aug 2013

Chemicals added to swimming pool water can cause irritation, injury and even death, doctors warn

Chemicals are added to swimming pool water to enhance and protect the water quality and minimize disease-causing germs, but these same chemicals can cause irritation, injury and even death when not handled appropriately, doctors at Vanderbilt University Medical Center warn.

1 Aug 2013

Study: Exposure to high altitude can cause acute mountain sickness, cerebral or pulmonary edema

"Exposure to high altitude can cause acute mountain sickness (AMS) and, in severe cases, cerebral or pulmonary edema. Capillary leakage has been hypothesized to play a role in the pathogenesis of AMS, although the mechanism of altitude-related illnesses remains largely unknown," writes Gabriel Willmann, M.D., of the University of Tubingen, Germany, and colleagues.

5 Jun 2013

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Baxter International Inc. today announced that its Phase III clinical study of immunoglobulin did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

From Baxter International Inc. 8 May 2013

European Commission grants conditional marketing authorization for Pfizer's BOSULIF

Pfizer Inc. announced today that the European Commission has granted conditional marketing authorization for BOSULIF (bosutinib) in the European Union for the treatment of adult patients with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

28 Mar 2013

Lung congestion increases dialysis patients' risks of premature death or heart attacks

Asymptomatic lung congestion increases dialysis patients' risks of dying prematurely or experiencing heart attacks or other cardiac events, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

1 Mar 2013

Wyss Founding Director receives NC3Rs 3Rs Prize for Lung-on-a-Chip

In a London ceremony today, Wyss Founding Director Don Ingber, M.D., Ph.D., received the NC3Rs 3Rs Prize from the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) for his innovative Lung-on-a-Chip -- a microdevice lined by human cells that recapitulates complex functions of the living lung.

28 Feb 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

No significant difference in patient outcomes with RBC transfusions using lower threshold levels

The level at which red blood cells are transfused, a common treatment in clinical practice, is often deliberated among physicians. Guidelines for blood transfusion levels were only recently issued in March 2012 diminishing some of the debate. Today, in a new section called JAMA Clinical Evidence Synopsis, the Journal of the American Medical Association (JAMA), published a summary of the systematic review of the 19 clinical trials that compare higher versus lower hemoglobin thresholds in red blood cell transfusion.

3 Jan 2013

Surgery poses cardiac risk to lupus women

Women with systemic lupus erythematosus are at significantly increased risk for short-term perioperative adverse cardiovascular events, find researchers.

17 Dec 2012

Brain effects of high-altitude sickness retained long term

Mountaineers who experience high-altitude cerebral edema often retain traces of the bleed in their brains for many years afterward, show study findings.

28 Nov 2012

Brain microhemorrhages more common among high altitude cerebral edema survivors

New magnetic resonance imaging (MRI) research shows that mountain climbers who experience a certain type of high altitude sickness have traces of bleeding in the brain years after the initial incident, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

28 Nov 2012

Study analyzes effectiveness of ultrasonography in diagnosis and treatment of critical care patients

A study published in the October issue of Anesthesiology analyzed the effectiveness of ultrasound examination in the diagnosis and treatment of critical care patients. In particular, the study looked at the ability of ultrasound to detect hidden anomalies, prompt urgent changes in therapy, induce further testing or interventions, and confirm or modify diagnoses.

20 Sep 2012

Pfizer receives FDA approval for BOSULIF to treat Ph+ chronic myelogenous leukemia

Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved BOSULIF (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.

6 Sep 2012

Greater awareness of MH and consequences of ryanodine receptor gene mutations

From the MHAUS President's Blog by MHAUS President, Henry Rosenberg, MD. A few months ago, I received a call from the MH Hotline who connected me to an anesthesiologist and OR team who were desperately trying to manage a Malignant Hyperthermia crisis.

26 Jun 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

Mayo Clinic researchers join expedition to Everest

It's a natural laboratory for studying heart disease, lung problems, muscle loss, sleeping disorders and new medical technologies. It's also the highest mountain in the world. Mount Everest's extreme altitude puts climbers under the same conditions experienced by patients suffering from heart disease, obesity or advanced age. To take advantage of that, Mayo Clinic researchers are joining an expedition to Everest with National Geographic, The North Face and Montana State University.

26 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012